These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2516011)

  • 21. A novel, automated method of temperature cycling to produce cryoprecipitate.
    Rock G; Berger R; Lange J; Tokessy M; Palmer DS; Giulivi A
    Transfusion; 2001 Feb; 41(2):232-5. PubMed ID: 11239228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Danazol in Indian haemophiliacs.
    Sundar S; Moorleedhur-Singh GS; Dube B; Singh VP; Kumar K
    J Assoc Physicians India; 1993 Jan; 41(1):23-5. PubMed ID: 8340322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
    Prowse CV
    Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII.
    El-Ekiaby M; Goubran HA; Radosevich M; Abd-Allah A; El-Ekiaby A; Burnouf T
    Haemophilia; 2011 Sep; 17(5):e884-8. PubMed ID: 21371202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the 'Mason' (continuous-thaw-siphon) method for cryoprecipitate production.
    Prowse CV; McGill A
    Vox Sang; 1979; 37(4):235-43. PubMed ID: 386613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A.
    Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P; Jitpraphai C; Hathirat P; Nuchprayoon C
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S69-73. PubMed ID: 10730521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M; Anders O; Schmidt M; Roewer J
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
    Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
    Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV; Silva IA; Borrasca AL
    Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of methods of plasma volume determination for dose calculation of factor VIII in patients with classic haemophilia.
    Ockelford PA; Lowe G; Johns AS; Berry EW
    N Z Med J; 1986 Feb; 99(796):116-9. PubMed ID: 3081842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S; Ziemski JM
    Acta Haematol Pol; 1979; 10(2):115-22. PubMed ID: 474044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased yield of F VIII from pooled plasma vs. single-donor plasma in the production of cryoprecipitates.
    Rácz Z; Thék M; Jánossy A; Pintér J; Baróti C
    Arch Med Res; 1997; 28(2):179-82. PubMed ID: 9204605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microwave-thawed plasma for cryoprecipitate production.
    Bass H; Trenchard PM; Mustow MJ
    Vox Sang; 1985; 48(2):65-71. PubMed ID: 3934842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thaw-siphon technique for factor-VIII cryoprecipitate.
    Das PC; Smit Sibinga CT
    Lancet; 1978 Jul; 2(8083):273. PubMed ID: 79076
    [No Abstract]   [Full Text] [Related]  

  • 37. Fibrinogen in cryoprecipitate and its relationship to factor VIII (AHF) levels.
    Ness PM; Perkins HA
    Transfusion; 1980; 20(1):93-6. PubMed ID: 7355478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cryoprecipitate prepared from plasma frozen within 24 hours after phlebotomy contains acceptable levels of fibrinogen and VIIIC.
    Yazer MH; Triulzi DJ; Hassett AC; Kiss JE
    Transfusion; 2010 May; 50(5):1014-8. PubMed ID: 20003046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of height and weight on the in vivo recovery of transfused factor VIII C.
    Aronstam A; McLellan DS; Wassef M; Mbatha PS
    J Clin Pathol; 1982 Mar; 35(3):289-91. PubMed ID: 6802879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
    Over J; Sixma JJ; Bruïne MH; Trieschnigg MC; Vlooswijk RA; Beeser-Visser NH; Bouma BN
    J Clin Invest; 1978 Aug; 62(2):223-34. PubMed ID: 670391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.